New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 13, 2014
05:17 EDTKPTIKaryopharm announces first combination data of Selinexor Phase 1 trial
Karyopharm Therapeutics announced initial Phase 1 data from patients with multiple myeloma treated with Karyopharm's lead selective inhibitor of nuclear export, or SINE, Selinexor, in combination with "low-dose" dexamethasone. Among eight patients, the best responses were one stringent complete response, or sCR, three partial responses, or PRs, two minor responses, or MRs, one progressive disease and one non-evaluable. Accordingly, the clinical benefit response rate is 75% and the overall response rate. Adverse events in patients receiving single-agent Selinexor were generally low-grade, consistent with events observed in patients with other hematological malignancies and responsive to standard supportive care. Compared with Selinexor given alone, fewer adverse events in patients receiving Selinexor in combination with dexamethasone were reported, consistent with dexamethasone's reduction in Selinexor's main side effects of nausea, anorexia, and fatigue.
News For KPTI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 19, 2015
08:53 EDTKPTIConcerns over Karyopharm overdone, says Wedbush
After eight AML patients taking Karyopharm's Sellinexor developed Sepisis versus two in the control arm, Wedbush quotes a doctor as saying that differences in patients' characteristics between the two arms may have contributed to the high rate of Sepsis in those taking Sellinexor,. Wedbush believes that a study of the 60 mg version of the drug, due out in 4Q16, will show that it improves survival and has an acceptable safety profile. Wedbush increased its discount rate on AML to 45% from 30% to account for higher risk from a reduced dose and cut its price target on the name to $39 from $50, mostly due to the postponement of clinical trial results. However, the firm keeps an Outperform rating on the shares.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use